SSaakyan S.V., Tsygankov А.Y., Zhil'tsova M.G., Tadevosyan S.S., Moiseeva N.I., Karamysheva А.F. Retinoblastoma cell culturing and evaluation of their drug resistance. Bulletin of Experimental Biology and Medicine. 2018. Т. 165. № 1. С. 148-153.
Sarici A., Kizilkilic O., Celkan T., Gode S. Blue toe syndrome as a complication of intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmol. 2013 Jun;131(6):801-2.
doi: 10.1001/jamaophthalmol.2013.1458.
https://pubmed.ncbi.nlm.nih.gov/23764710/ Scelfo C., Francis J.H., Khetan V., Jenkins T., Marr B., Abramson D.H. et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol 2017;10:961-7.
doi: 10.18240/ijo.2017.06.20.
https://pubmed.ncbi.nlm.nih.gov/28730089/ Christina Scelof, Jasmine H Francis, Vikas Khetan, Thomas Jenkins , Brian Marr, David H Abramson, Carol L Shields, Jacob Pe'er, Francis Munier, Jesse Berry, J. William Harbour, Andrey Yarovoy, Evandro Lucena, Timothy G Murray, Pooja Bhagia, Evelyn Paysse, Samuray Tuncer, Guillermo L Chantada, Annette C Moll, Tatiana Ushakova, David A Plager, Islamov Ziyovuddin, Carlos A Leal, Miguel A Materin, Xun-Da Ji, Jose W Cursino, Rodrigo Polania, Hayyam Kiratli, Charlotta All-Ericsson, Rejin Kebudi, Santosh G Honavar, Vicktoria Vishnevskia-Dai, Sidnel Epelman, Anthony B Daniels, Jeanie D Ling, Fousseyni Traore, Marco A Ramirez-Ortiz. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol 2017; 10(6):961-967
Schaiquevich P., Ceciliano A., Millan N., Taich P., Villasante F., Fandino A.C., Dominguez J., Chantada G.L. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013 May;60(5):766-70. Epub 2012 Sep 28.
doi: 10.1002/pbc.24356.
https://pubmed.ncbi.nlm.nih.gov/23024125/
Schaiquevich P., Fabius A.W., Francis J.H., Chantada G.L., Abramson D.H. Ocular pharmacology of chemotherapy for retinoblastoma.Retina.2017. 37:1–10.
DOI: 10.1097/IAE.0000000000001275.
https://www.ncbi.nlm.nih.gov/pubmed/27617542 Schefler A.C., Braich P.S. Local chemotherapy. In: Ramasubramanian A, Shields C.L., editors.Retinoblastoma.New Delhi, India: Jaypee Brothers Medical Publishers. 2012. pp. 99-108.
Schefler A.C., Kim R.S. Recent advancements in the management of retinoblastoma and uveal melanoma. F1000Res 2018; 7:F1000 Faculty Rev-476.
doi: 10.12688/f1000research.11941.1
https://pubmed.ncbi.nlm.nih.gov/29755733/ Schlienger P., Campana F., Vilcoq J.R., Asselain B. et al. Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM. Am J Clin Oncol. 2004 Aug;27(4):411-9.
doi: 10.1097/01.coc.0000128861.46357.ee
Schlueter S., Metz K., Bornfeld N., Göricke S., Schlamann M., Sirin S., Biewald E.. Intraokulare Raumforderungen im Kindesalter ohne Retinoblastom [Intraocular Tumors other than Retinoblastoma in Children]. Klin Monbl Augenheilkd. 2015 Jul;232(7):838-44. German.
doi: 10.1055/s-0041-102899.
https://pubmed.ncbi.nlm.nih.gov/26193116/ Schouten-van Meeteren A.Y.N. et al. Chemotherapy for retinoblastoma: An expanding area of clinical research // Medical and Pediatric Oncology. 2002. Vol. 38, № 6. P. 428–438.
DOI:
10.1002/mpo.1358 https://onlinelibrary.wiley.com/doi/abs/10.1002/mpo.1358 Schouten-van Meeteren A.Y. et al. Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay. // Cancer. 2001. Vol. 92, № 11. P. 2933–2940.
PMID: 11753969
https://pubmed.ncbi.nlm.nih.gov/11753969/ Schueler A.O., Flühs D., Anastassiou G. et al. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. International Journal of radiation oncology, biology, physics. 2006. 65(4): 1212–21.
DOI: 10.1016/j.ijrobp.2006.02.002
https://www.ncbi.nlm.nih.gov/pubmed/16682139 Schueler A.O., Flühs D., Anastassiou G., Jurklies C., Sauerwein W., Bornfeld N. Beta-Ray Brachytherapy of Retinoblastoma: Feasibility of a New Small-Sized Ruthenium-106 Plaque. Ophthalmic Res 2006; 38(1):8–12.
doi: 10.1159/000088259
https://pubmed.ncbi.nlm.nih.gov/16166817/Schueler A.O., Hosten N., Bechrakis N.E. et al. High resolution magnetic resonance imaging of retinoblastoma // British Journal of Ophthalmology. 2003. Vol. 87. P. 330-335.
DOI: 10.1136/bjo.87.3.330
https://www.ncbi.nlm.nih.gov/pubmed/12598449 Schüler A., Weber S., Neuhäuser M. et al. Age at diagnosis of isolated unilateral retinoblastoma does not distinguish patients with and without a constitutional RB1 gene mutation but is influenced by a parent-of-origin effect. Eur J Cancer. 2005;41(5):735-74015763650
DOI:
10.1016/j.ejca.2004.12.022 https://www.ejcancer.com/article/S0959-8049(05)00022-5/fulltext
Schündeln M.M., Hauffa P.K., Bauer J.J., Temming P., Sauerwein W., Biewald E., Bornfeld N., Hauffa B.P., Grasemann C. Pediatric Survivors of Retinoblastoma Are at Risk for Altered Bone Metabolism After Chemotherapy Treatment Early in Life. Pediatr Hematol Oncol. 2015;32(7):455-66.
doi: 10.3109/08880018.2015.1048912.
https://pubmed.ncbi.nlm.nih.gov/26237585/
Sedghizadeh P.P., Angiero F., Allen C.M., Kalmar J.R., Rawal Y., Albright E.A. Post-irradiation leiomyosarcoma of the maxilla: report of a case in a patient with prior radiation treatment for retinoblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jun;97(6):726-31.
doi: 10.1016/j.tripleo.2003.11.017.
https://pubmed.ncbi.nlm.nih.gov/15184855/ Seregard S., Lundell G., Svedberg H., Kivelä T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology. 2004; 111(6):1228-123215177976
https://www.aaojournal.org/article/S0161-6420(04)00138-1/fulltext
Seregard S., Singh A.D. Retinoblastoma: Direct chemotherapeutic drug delivery into the vitreous cavity. British Journal of Ophthalmology.2012. 96:473-4.
DOI: 10.1136/bjophthalmol-2012-301528.
https://bjo.bmj.com/content/96/4/473 Seth R., Singh A., Guru V., Chawla B., Pathy S., Sapra S. Long-term follow-up of retinoblastoma survivors: Experience from India. South Asian J Cancer. 2017 Oct-Dec;6(4):176-179.
doi: 10.4103/sajc.sajc_179_16
https://pubmed.ncbi.nlm.nih.gov/29404299/
Shah C., Hughes M., Kirzhner M. Anophthalmic syndrome: A review of management // Ophthal. Plast. Reconstr. Surg. 2014. № 5. P. 361–365.
DOI:10.1097/ IOP.0000000000000217
Shah S., Shields C., Lally S., Shields J. Hydroxyapatite orbital implant in children following enucleation: analysis of 531 sockets // Ophthal. Plast. Reconstr. Surg. 2015. № 31. Р. 108-114.
Shahsavari M., Mashayekhi A. Pharmacotherapy for retinoblastoma. // J. Ophthalmic Vis.Res. 2009. Vol. 4, № 3. P. 169–173.
PMID: 23198068; PMCID: PMC3498564.
https://pubmed.ncbi.nlm.nih.gov/23198068/
Shah V., Yadav L., Singh M., Kharbanda S. Custom ocular prosthesis in rehabilitation of a child operated for retinoblastoma. Natl J Maxillofac Surg. 2015 Jul-Dec;6(2):232-6.
doi: 10.4103/0975-5950.183871.
https://pubmed.ncbi.nlm.nih.gov/27390504/
Shanmugan М.Р., Biswas J., Gopal L. et al. The clinical spectrum and treatment outcome of retinoblastoma in Indian children // Journal of Pediatric Ophthalmology and Strabismus. 2005. Vol. 42. P. 75-81.
https://www.ncbi.nlm.nih.gov/pubmed/15825743 Shetty O.A., Naresh K.N., Banavali S.D. et al. Evidence for the presence of high risk human papillomavirus in retinoblastoma tissue from nonfamilial retinoblastoma in developing countries // Pediatric Blood & Cancer.2012. Vol. 58. P. 185-190.
DOI: 10.1002/pbc.23346.
https://www.ncbi.nlm.nih.gov/pubmed/22021092 Shields C.L. EDI-OCT of Intraocular Tumors // Retina Today. Nov/Dec, 2013. P. 62-65.
http://retinatoday.com/pdfs/1113RT_F5_Shields.pdf Shields C.L., Alset A.E., Say E.A., Caywood E., Jabbour P., Shields J.A. Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era. Journal of Pediatric Ophthalmology and Strabismus. 2016. 53. 275–84.
DOI: 10.3928/01913913-20160719-04.
https://www.ncbi.nlm.nih.gov/pubmed/27486728 Shields C.L., Bianciotto C.G., Jabbour P. et al. Intra-arterial chemotherapy for retinoblastoma: report № 2, treatment complications. Archives of Ophthalmology. 2011; 129(11): 1407-1415.
DOI: 10.1001 /archophthalmol. 2011. 151.
https://www.ncbi.nlm.nih.gov/pubmed/21670326Shields C.L., Bianciotto C.G., Jabbour P., Ramasubramanian A., Lally S.E., Griffin G.C. et al. Intra-arterial chemotherapy for retinoblastoma: Report No 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Archives of Ophthalmology. 2011. 129 1399-406.
DOI: 10.1001/archophthalmol.2011.150.
https://www.ncbi.nlm.nih.gov/pubmed/21670328
Shields C.L., Douglass A.M., Beggache M. et al. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture. Retina2016;36:1184–1190/
doi: 10.1097/IAE.0000000000000903.
https://insights.ovid.com/article/00006982-201606000-00019 Shields C.L., Fulco E.M., Arias J.D. et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy // Eye (London). 2013. Vol. 27. N 2. P. 253-64.
DOI:
10.1038/eye.2012.175 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574237/
Shields C.L., Honavar S.G., Shields J.A., Demirci H., Meadows A.T., Naduvilath T.J. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120(4):460–4. PMID: 11934319.
https://pubmed.ncbi.nlm.nih.gov/11934319/Shields C.L., Jorge R., Say E.A., Magrath G., Alset A., Caywood E., Leahey A.M., Jabbour P., Shields J.A. Unilateral Retinoblastoma Managed With Intravenous Chemotherapy Versus Intra-Arterial Chemotherapy. Outcomes Based on the International Classification of Retinoblastoma. Asia Pac J Ophthalmol (Phila). 2016 Mar-Apr;5(2):97-103.
doi: 10.1097/APO.0000000000000172.
https://pubmed.ncbi.nlm.nih.gov/26765038/ Shields C.L., Kaliki S., Al-Dahmash S., Rojanaporn D., Leahey A., Griffin G. et al. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation.Retina.2013; 33:2103–9
DOI: 10.1097/IAE.0b013e318295f783.
https://www.ncbi.nlm.nih.gov/pubmed/23873161Shields C.L., Kaliki S., Rojanaporn D., Al-Dahmash S., Bianciotto C.G., Shields J.A. Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned. Curr Opin Ophthalmol 2012;23(3):202–9.
doi: 10.1097/ICU.0b013e3283524130
https://pubmed.ncbi.nlm.nih.gov/22450222/Shields C.L., Kaliki S., Shah S.U. et al. Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Ophthalmology. 2012;119(1):188-192. tha.2011.06.036.
DOI: 10.1016/j.ophtha.2011.06.036.
https://www.ncbi.nlm.nih.gov/pubmed/21975042
Shields C.L., Lally S.E., Leahey A.M., Jabbour P.M., Caywood E.H., Schwendeman R., Shields J.A. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol. 2014 Sep;25(5):374-85.
doi: 10.1097/ICU.0000000000000091.
https://pubmed.ncbi.nlm.nih.gov/25014750/Shields C.L., Manjandavida F.P., Arepalli S., Kaliki S., Lally S.E., Shields J.A. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: Preliminary results. JAMA Ophthalmology. 2014. 132.319-25.
DOI: 10.1001/jamaophthalmol.2013.7666.
https://www.ncbi.nlm.nih.gov/pubmed/24407202 Shields C.L., Manjandavida F.P., Pieretti G., Arepalli S.A., Jabbour P., Shields J.A. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014. 121:1453-6.
DOI: 10.1016/j.ophtha.2014.01.026.
https://www.ncbi.nlm.nih.gov/pubmed/24656794
Shields С.L., Mashayekhi A., Au A.K. et al. The International Classification of Retinoblastoma Predicts Chemoreduction Success // Ophthalmology. 2006. Vol. 113. P. 2276-2280.
DOI: 10.1016/j.ophtha.2006.06.018
https://www.ncbi.nlm.nih.gov/pubmed/16996605
Shields C.L., Mashayekhi A., Demirci H. et al. Practical approach to management of retinoblastoma. Archives of Ophthalmology. 2004; 122(5): 729-735.
DOI: 10.1001/ archopht.122.5.729.
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/416286 Shields C.L., Mashayekhi A., Sun H., Uysal Y., Friere J., Komarnicky L., Shields J.A. Iodine 125 Plaque Radiotherapy as Salvage Treatment for Retinoblastoma Recurrence after Chemoreduction in 84 Tumors. Ophthalmology 2006; 113(11):2087–92.
doi: 10.1016/j. ophtha.2006.04.032
https://pubmed.ncbi.nlm.nih.gov/16949158/
Shields C.L., Meadows A.T., Shields J.A., Carvalho C., Smith A.F. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Archives of Ophthalmology.2001. 119:1269–72.
DOI: 10.1001/archopht.119.9.1269
https://www.ncbi.nlm.nih.gov/pubmed/11545631
Shields C.L., Meadows A.T., Leahey A.M., Shields J.A. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina. 2004 Dec;24(6):849-62.
doi: 10.1097/00006982-200412000-00003.
https://pubmed.ncbi.nlm.nih.gov/15579981/Shields С.L., Palamar M., Sharma P.et al. Retinoblastoma Regression Patterns Following Chemoreduction and Adjuvant Therapy in 557 Tumors // Archieves of Ophthalmology. 2009. Vol. 127. N 3. P. 282-290.
DOI: 10.1001/archophthalmol.2008.626.
https://www.ncbi.nlm.nih.gov/pubmed/19273791 Shields C.L., Ramasubramanian A., Thangappan A., Hartzell K., Leahey A., Meadows A.T. et al. Chemoreduction for group E retinoblastoma: Comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology. 2009. 116:544–51.e1
DOI: 10.1016/j.ophtha.2008.10.014.
https://www.ncbi.nlm.nih.gov/pubmed/19157557
Shields C.L., Say E.A.T., Pefkianaki M., Regillo C.D., Caywood E.H., Jabbour P.M. et al. Rhegmatogenous retinal detachment after intraarterial chemotherapy for retinoblastoma: The 2016 founders award lecture. Retina 2017;37:1441-50.
doi: 10.1097/IAE.0000000000001382.
https://pubmed.ncbi.nlm.nih.gov/27787452/
Shields C.L., Say E.A., Pointdujour-Lim R., Cao C., Jabbour P.M., Shields J.A. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy. J Fr Ophtalmol 2015;38(6):542–9. doi: 10.1016/j.jfo.2015.03.004
https://pubmed.ncbi.nlm.nih.gov/25982423/
Shields C.L., Shelil A., Cater J. et al. Development of new retinoblastoma as after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Archives of Ophthalmology. 2003;121(11):1571-1576
DOI: 10.1001/archopht.121.11.1571.
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/415842
Shields C.L., Shields J.A. Diagnosis and management of retinoblastoma // Cancer Control. 2004. Vol. 11. N 5. Р. 317-327.
DOI: 10.1177/107327480401100506
https://www.ncbi.nlm.nih.gov/pubmed/15377991
Shields C.L., Shields J.A. Intra-arterial chemotherapy for retinoblastoma: The beginning of a long journey // Clinical and Experimental Ophthalmology. 2010. Vol. 38, № 6. P. 638–643.
DOI:
10.1111/j.1442-9071.2010.02297.xhttps://pubmed.ncbi.nlm.nih.gov/20584015/
Shields C.L., Shields J.A. Intra-arterial Chemotherapy for Retinoblastoma. JAMA Ophthalmol. 2016 Oct 1;134(10):1201.
doi: 10.1001/jamaophthalmol.2016.2712.
https://pubmed.ncbi.nlm.nih.gov/27533705/
Shields C.L., Shields J.A. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010 May;21(3):203-12.
doi: 10.1097/ICU.0b013e328338676a.
https://pubmed.ncbi.nlm.nih.gov/20224400/
Shields C.L., Shields J.A., Cater J., Othmane I., Singh A.D., Micaily B. Plaque radiotherapy for retinoblastoma. Long-term tumor control and treatment complications in 208 tumors. Ophthalmology 2001;108(11):2116–21.
doi: 10.1016/s0161-6420(01)00797-7
https://pubmed.ncbi.nlm.nih.gov/11713089/
Shields C.L., Shields J.A., Lally S.E., Eagle RC. Jr. Harvesting fresh tumor tissue from enucleated eyes: the 2008 Jack S. Guyton lecture. Arch Ophthalmol. 2010;128(2):241-24320142549
DOI: 10.1001/archophthalmol.2009.396
https://jamanetwork.com/journals/jamaophthalmology... Shields C.L., Shields J.A. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus. 1999 Jan-Feb;36(1):8-18; quiz 35-6. PMID: 9972509.
doi: 10.3928/0191-3913-19990101-04
Shields C.L., Uysal Y., Marr B.P., Lally S.E., Rodriques E., Kharod B., Shields J.A. Experience with the polymer-coated hydroxyapatite implant after enucleation in 126 patients. Ophthalmology. 2007 Feb;114(2):367-73.
doi: 10.1016/j.ophtha.2006.08.030.
https://pubmed.ncbi.nlm.nih.gov/17270685/ Shields J., Shields C. Retinoblastoma: introduction, genetics, clinical features, classification // Shields J., Shields C., Eds. Atlas of Intraocular Tumors, 3rd ed., Philadelphia: Lippinocott, Wolters Kluwer; 2016. p. 311-314
Shildkrot Y., Kirzhner M., Haik B.G., Qaddoumi I., Rodriguez-Galindo C., Wilson M.W. The effect of cancer therapies on pediatric anophthalmic sockets // Ophthalmology. 2011. № 12. P. 2480–2486.
DOI: 10.1016/j.ophtha.2011.05.024
Shimoda Y., Hamano R., Ishihara K., Shimoda N., Hagimura N., Akiyama H., Kishi S., Kaneko A. Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):501-8. Epub 2007 Oct 13.
doi: 10.1007/s00417-007-0685-3.
https://pubmed.ncbi.nlm.nih.gov/17934752/
Simpson E.R., Gallie B., Laperrierre N., Beiki-Ardakani A., Kivelä T. et al. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13(1):1–14.
doi: 10.1016/j.brachy.2013.11.008
https://pubmed.ncbi.nlm.nih.gov/24373763/ Singh H.P., Wang S., Stachelek K., Lee S. Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors. 2018, Proc. Natl. Acad. Sci. U. S. A. 115, E9391–E9400.
https://doi.org/10.1073/pnas.1808903115 Sirin S., de Jong M.C., de Graaf P., Brisse H.J., Galluzzi P., Maeder P., Bornfeld N., Biewald E., Metz K.A., Temming P., Castelijns J.A., Goericke S.L.; European Retinoblastoma Imaging Collaboration. High-Resolution Magnetic Resonance Imaging Can Reliably Detect Orbital Tumor Recurrence after Enucleation in Children with Retinoblastoma. Ophthalmology. 2016 Mar;123(3):635-45.
DOI: 10.1016/j.ophtha.2015.10.054.
Sirin S., Schlamann M., Metz K.A., Bornfeld N., Schweiger B., Holdt M., Temming P., Schuendeln M.M., Goericke S.L. High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: Part 1: MRI vs. histopathology. Neuroradiology. 2015 Aug;57(8):805-14.
DOI: 10.1007/s00234-015-1544-2.
https://www.ncbi.nlm.nih.gov/pubmed/26041632 Sirin S., Schlamann M., Metz K.A., Bornfeld N., Schweiger B., Holdt M., Temming P., Schuendeln M.M., Goericke S.L. High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: Part 1: new vs. old imaging concept. Neuroradiology. 2015 Aug;57(8):805-14.
DOI: 10.1007/s00234-015-1538-0.
https://www.ncbi.nlm.nih.gov/pubmed/25964026 Sivakumaran T.A., Ghose S., Kumar H., Kucheria K. Parental age in Indian patients with sporadic hereditary retinoblastoma // Ophthalmic Epidemiology. 2000. N 7. P. 285-291.
DOI: 10.1076/opep.7.4.285.4172
https://www.ncbi.nlm.nih.gov/pubmed/11262675 Skalet A.H., Gombos D.S., Gallie B.L., Kim J.W., Shields C.L., Marr B.P., Plon S.E., Chévez-Barrios P. Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018 Mar;125(3):453-458.
DOI: 10.1016/j.ophtha.2017.09.001
https://www.aaojournal.org/article/S0161-6420(17)31784-0/references
Smith S.J., Pulido J.S., Salomão D.R., Smith B.D., Mohney B. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. British Journal of Ophthalmology.2012. 96:1073-7.
DOI: 10.1136/bjophthalmol-2011-300829.
https://www.ncbi.nlm.nih.gov/pubmed/22368261 Smith S.J., Smith B.D. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013.
DOI:
10.1136/bjophthalmol-2013-303188 https://bjo.bmj.com/content/97/10/1231 Smith S.J., Smith B.D., Mohney B.G. Ocular side effects following intravitreal injection therapy for retinoblastoma: A systematic review. British Journal of Ophthalmology. 2014. 98. 292-7.
DOI: 10.1136/bjophthalmol-2013-303885.
https://www.ncbi.nlm.nih.gov/pubmed/24187047 Sohajda Z., Damjanovich J., Bárdi E., Szegedi I., Berta A., Kiss C. Combined Local Treatment and Chemotherapy in the Management of Bilateral Retinoblastomas in Hungary. J Pediatr Hematol Oncol 2006; 28(6):399–401.
doi: 10.1097/00043426-200606000-00016
https://pubmed.ncbi.nlm.nih.gov/16794512/Soliman S.E., Racher H., Zhang C., MacDonald H., Gallie B.L., 2017. Genetics and molecular diagnostics in retinoblastoma–an update. Asia Pac J Ophthalmol (Phila) 6, 197–207.
https://doi.org/10.22608/APO.201711
Soliman S.E., VandenHoven C., Mackeen L.D., Gallie B.L. Vision and visual potential for perifoveal retinoblastoma after optical coherence tomographic-guided sequential laser photocoagulation. Br J Ophthalmol. 2019 Jun;103(6):753-760.
DOI: 10.1136/bjophthalmol-2018-312125
https://www.ncbi.nlm.nih.gov/pubmed/29976784
Soliman S.E., VandenHoven C., Mackeen L.D., Heon E., Gallie B.L. Optical Coherence Tomography-Guided Decisions in Retinoblastoma Management. Ophthalmology. 2017 Jun;124(6):859-872.
DOI: 10.1016/j.ophtha.2017.01.052
Stannard C., Sauerwein W., Maree G., Lecuona K. Radiotherapy for ocular tumours. Eye 2013; 27(2):119–27.
doi: 10.1038/eye.2012.241
https://pubmed.ncbi.nlm.nih.gov/23174750/Stenzel E., Göricke S., Temming P., Biewald E., Zülow S., Göbel J. et al. Feasibility of intra-arterial chemotherapy for retinoblastoma: Experiences in a large single center cohort study. Neuroradiology.2019.61:351–7.
DOI: 10.1007/s00234-019-02153-9.
https://www.ncbi.nlm.nih.gov/pubmed/30643921 Sullivan E.M., Wilson M.W., Billups C.A., et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014; 36(6):e335-e340.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41085... Sultan I., Hajja Y., Nawaiseh I., Mehyar M., Deebajah R., Jaradat I., Yousef Y.A. Chemoreduction of Progressive Intraocular Retinoblastoma by Systemic Topotecan. Ophthalmic Genet 2016;37(2):209–13.
doi: 10.3109/13816810.2015.1039138.
https://pubmed.ncbi.nlm.nih.gov/26760494/ Suzuki S., Aihara Y., Fujiwara M., Sano S., Kaneko A. Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol. 2015 May;59(3):164-72.
doi: 10.1007/s10384-015-0378-0.
https://pubmed.ncbi.nlm.nih.gov/25808017/Suzuki S., Yamane T., Mohri M., Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011; 118(10): 2081-2087.
DOI: 10.1016/j.ophtha.2011.03.013
https://www.ncbi.nlm.nih.gov/pubmed/21715012